Tecan and Attana extend distribution agreement
Publication date: 12 October 2011
Author: kdm communications
Tagged with: Andrea Becarri, Attana AB, Tecan, Teodor Aastrup
Tecan and Attana AB have announced an extended distribution agreement under which Tecan will distribute Attana’s label-free biosensor instruments and quartz crystal microbalance (QCM) assay technology in Europe.
Attana Cell 200 system
This collaboration covers the Attana 100, Attana 200 and Cell 200 instruments, as well as biosensors and assay reagents, service and support, extending the existing agreement for North America announced earlier this year. Exceptions to this agreement are Scandinavia and those countries covered by Tecan’s distributor network. This distribution agreement will ensure customers in these new markets can take advantage of QCM technology for analysis of molecular interactions in a wide variety of research applications, supported by Tecan’s sales, service and applications capabilities.
“We are pleased to announce this expansion only six months after our initial agreement with Tecan for North America,” commented Teodor Aastrup, CEO and founder of Attana. “This collaboration will strengthen Attana’s position in Europe through Tecan’s broad sales channels and local presence. Our products complement each other well, and we are able to offer customers a complete solution for biomolecular investigation.”
Andrea Becarri, Global Head of Commercial, at Tecan, added: “Extension of our agreement with Attana will ensure customers receive the highest level of support for their applications, helping them to make the most of this innovative technology with the assistance of Tecan’s knowledgeable sales and service personnel.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
- New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine (18 May 2012)
- NUCYNTA® ER (tapentadol) tablets provide pain management for patients with Diabetic Peripheral Neuropathy (DPN) (18 May 2012)
- GSK statement on tender offer to acquire Human Genome Sciences (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content